The bumping of Pharma elephants: Pfizer and Wyeth
Columnist Michael Rosen predicted an interesting year in the life science realm, thanks in part to expiring patents, and so far he's been spot on. In this edition of Yer Biotech Blues, he cites Pfizer's acquisition of Wyeth as an example of what's ahead, and...